Opdivo is the first and only PD-1 inhibitor approved for subcutaneous (SC) use in the European Union Approval is based on results from the Phase 3 CheckMate -67T clinical trial which demonstrated ...
Bristol Myers Squibb BMY announced positive top-line results from the CheckMate -648 study on Opdivo in combination with chemotherapy. CheckMate -648 is a randomized phase III study evaluating Opdivo ...
Swallowable sampling device combined with methylation biomarker panel IDs Barrett esophagus. The approvals are based on data from the phase 3 CheckMate-648 trial, which included 970 adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback